Viatris Inc

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$44.5M

Filings

276

Firms Hired

Active Period

1999–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$1,300,000	9	3
2025	$2,310,000	15	4
2024	$2,550,000	20	5
2023	$2,810,000	23	6
2022	$2,830,000	24	6
2021	$3,090,000	32	7
2020	$2,830,000	31	7
2019	$4,060,000	20	5
2018	$2,910,000	20	5
2017	$2,660,000	8	2
2016	$2,275,000	10	2
2015	$1,940,000	10	2
2014	$1,260,000	4	1
2013	$1,810,000	5	1
2012	$2,250,313	5	1
2011	$1,742,123	4	1
2010	$1,500,000	4	1
2009	$1,300,000	4	1
2008	$1,830,000	8	1
2007	$270,000	2	1
2006	$430,000	4	1
2005	$220,000	2	1
2004	$80,000	1	1
2003	$160,000	2	1
2002	$90,000	2	1
2001	$0	2	1
2000	$0	3	1
1999	—	2	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
Viatris Inc	$44,507,436	106
WEST FRONT STRATEGIES LLC	—	41
FEROX STRATEGIES	—	38
HOLLAND & KNIGHT LLP	—	31
BLUE RIDGE LAW & POLICY, P.C.	—	22
RAMPY NORTHRUP LLC	—	24
THEGROUP DC, LLC	—	14

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	266
SENATE	266
Centers For Medicare and Medicaid Services (CMS)	63
Health & Human Services, Dept of (HHS)	57
Commerce, Dept of (DOC)	30
Food & Drug Administration (FDA)	27
White House Office	26
U.S. Trade Representative (USTR)	21
Securities & Exchange Commission (SEC)	18
Federal Trade Commission (FTC)	16
Natl Economic Council (NEC)	15
Office of Management & Budget (OMB)	12
Executive Office of the President (EOP)	10
Program Support Center	5
Centers For Disease Control & Prevention (CDC)	4
Homeland Security, Dept of (DHS)	2
Transportation, Dept of (DOT)	2
Government Accountability Office (GAO)	1
Patent & Trademark Office (PTO)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	172
Copyright/Patent/Trademark	Copyright/Patent/Trademark	148
Budget/Appropriations	Budget/Appropriations	93
Trade (domestic/foreign)	Trade (domestic/foreign)	85
Pharmacy	Pharmacy	69
Financial Institutions/Investments/Securities	Financial Institutions/Investments/Securities	56
Medicare/Medicaid	Medicare/Medicaid	51
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	33
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	15
Foreign Relations	Foreign Relations	14
Defense	Defense	8
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	4
Veterans	Veterans	2
Homeland Security	Homeland Security	2

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 4132119th Congress

Prescription Information Modernization Act of 2025

2026 · third_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $450,000 · Firm income: —

Matched citations: HR 4132

S. 2027119th Congress

Prescription Information Modernization Act of 2025

2026 · third_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $450,000 · Firm income: —

Matched citations: S.2027

S. 2296119th Congress

National Defense Authorization Act for Fiscal Year 2026

2026 · third_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S.2296 National Defense Authorization Act

Client expense: $450,000 · Firm income: —

Matched citations: S.2296

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $450,000 · Firm income: —

Matched citations: S. 2658

Show 21 more cited filings

S. 3778119th Congress

Carbon Resource Innovation Act

2026 · third_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Client expense: $450,000 · Firm income: —

Matched citations: S.3778

S. 3841119th Congress

Last Sale Valuation Act of 2026

2026 · third_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Client expense: $450,000 · Firm income: —

Matched citations: S.3841

S. 891119th Congress

Bipartisan Health Care Act

2026 · third_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $450,000 · Firm income: —

Matched citations: S. 891

S. 1071119th Congress

National Defense Authorization Act for Fiscal Year 2026

2026 · third_quarter · Firm: FEROX STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).

Client expense: — · Firm income: $70,000

Matched citations: S. 1071

S. 1302119th Congress

Increasing Transparency in Generic Drug Applications Act

2026 · third_quarter · Firm: HOLLAND & KNIGHT LLP

Open original LDA filing ↗

Cited source text and reported amounts

S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; Drug Shortages; Medicaid Generics Penalty.

Client expense: — · Firm income: $50,000

Matched citations: S. 1302

H.R. 4132119th Congress

Prescription Information Modernization Act of 2025

2026 · second_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $360,000 · Firm income: —

Matched citations: HR 4132

S. 2027119th Congress

Prescription Information Modernization Act of 2025

2026 · second_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $360,000 · Firm income: —

Matched citations: S.2027

S. 2296119th Congress

National Defense Authorization Act for Fiscal Year 2026

2026 · second_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S.2296 National Defense Authorization Act

Client expense: $360,000 · Firm income: —

Matched citations: S.2296

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · second_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $360,000 · Firm income: —

Matched citations: S. 2658

S. 3778119th Congress

Carbon Resource Innovation Act

2026 · second_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Client expense: $360,000 · Firm income: —

Matched citations: S.3778

S. 3841119th Congress

Last Sale Valuation Act of 2026

2026 · second_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Client expense: $360,000 · Firm income: —

Matched citations: S.3841

S. 891119th Congress

Bipartisan Health Care Act

2026 · second_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

Client expense: $360,000 · Firm income: —

Matched citations: S. 891

S. 1071119th Congress

National Defense Authorization Act for Fiscal Year 2026

2026 · second_quarter · Firm: FEROX STRATEGIES

Open original LDA filing ↗

Cited source text and reported amounts

Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).

Client expense: — · Firm income: $70,000

Matched citations: S. 1071

S. 1302119th Congress

Increasing Transparency in Generic Drug Applications Act

2026 · second_quarter · Firm: HOLLAND & KNIGHT LLP

Open original LDA filing ↗

Cited source text and reported amounts

S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.

Client expense: — · Firm income: $50,000

Matched citations: S. 1302

H.R. 1843119th Congress

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

2026 · first_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

Client expense: $490,000 · Firm income: —

Matched citations: H.R. 1843

H.R. 4132119th Congress

Prescription Information Modernization Act of 2025

2026 · first_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

Client expense: $490,000 · Firm income: —

Matched citations: HR 4132

S. 1302119th Congress

Increasing Transparency in Generic Drug Applications Act

2026 · first_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

Client expense: $490,000 · Firm income: —

Matched citations: S. 1302

S. 1553119th Congress

PREVAIL Act

2026 · first_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act

Client expense: $490,000 · Firm income: —

Matched citations: S 1553

S. 2027119th Congress

Prescription Information Modernization Act of 2025

2026 · first_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

Client expense: $490,000 · Firm income: —

Matched citations: S.2027

S. 2296119th Congress

National Defense Authorization Act for Fiscal Year 2026

2026 · first_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S.2296 National Defense Authorization Act

Client expense: $490,000 · Firm income: —

Matched citations: S.2296

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · first_quarter · Firm: Viatris Inc

Open original LDA filing ↗

Cited source text and reported amounts

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

Client expense: $490,000 · Firm income: —

Matched citations: S.2658

Source: Senate LDA

Viatris Inc — Lobbying Disclosure | Poliscope